At Sanofi Pasteur, we aim to help control the COVID-19 pandemic through our:

Science in vaccine development

Large-scale manufacturing and supply capacities

Commitment to populations worldwide

A unique approach with 2 vaccine candidates

1. Recombinant-protein vaccine approach
   - The vaccine antigen is a key protein which will activate the body’s immune system to produce antibodies to fight against the virus if the body becomes infected.

2. mRNA vaccine approach
   - The vaccine stimulates the body cells to produce the key protein themselves. The immune system will respond to the key protein by producing antibodies.

Sanofi Pasteur and GSK
Recombinant Vaccine Candidate Update

Development
- Preclinical studies show promising safety and immunogenicity
- Phase 1/2 study show promising immunogenicity
- Phase 2 dose ranging study to enroll in February
- Phase 3 planned to start in May 2021

Capacity & Supply
- Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant
- Collaborative effort with BARDA to supply up to 100 million doses
- Agreement to supply the UK and EU
- GSK and Sanofi plan to supply a significant portion of total worldwide available supply in 2021/2022 to COVAX, the vaccines pillar of the ACT-Accelerator (Access to COVID-19 Tools)

Sanofi Pasteur and Translate Bio
mRNA Vaccine Candidate Update

Development
- Preclinical data shows that two immunizations of the mRNA vaccine induced high neutralizing antibody levels that are comparable to the upper range of those observed in infected humans
- Phase 1/2 study expected to start in March

Capacity & Supply
- Translate Bio has established mRNA manufacturing capacity and Sanofi expects to be able to supply annual capacity of 90 to 360 million doses.

THANK YOU

Photo credits: